Short Sleep Duration, Not OSA, Linked to Daytime Sleepiness
THURSDAY, April 4, 2019 -- Short sleep duration (SSD) is associated with daytime sleepiness, while obstructive sleep apnea (OSA) is associated with obesity, hypertension, and dyslipidemia, according to a study published online April 1 in CHEST.
Luciano F. Drager, M.D., Ph.D., from the University of Sao Paulo in Brazil, and colleagues examined the correlation of OSA, SSD, and their interactions with sleepiness and cardiometabolic risks in a large cohort of adults. Data were included for 2,064 participants who completed clinical evaluations, sleep questionnaires, home sleep monitoring, and actigraphy.
The researchers found that for OSA and SSD, the overall frequency was 32.9 and 27.2 percent, respectively. Excessive daytime sleepiness was independently associated with SSD after adjustment for multiple confounding factors (odds ratio, 1.448; 95 percent confidence interval, 1.172 to 1.790); no correlation was seen with OSA (odds ratio, 1.107; 95 percent confidence interval, 0.888 to 1.380). The SSD-OSA interaction was not significant. Independent associations with OSA were seen for prevalent obesity (odds ratio, 3.894; 95 percent confidence interval, 3.077 to 4.928), hypertension (odds ratio, 1.314; 95 percent confidence interval, 1.035 to 1.667), and dyslipidemia (odds ratio, 1.251; 95 percent confidence interval, 1.006 to 1.555); no independent associations were seen for SSD. The OSA-SSD interactions were not significant.
"Our findings suggest potential distinct clinical impacts of OSA and SSD," the authors write. "While SSD was more related to daytime sleepiness, OSA was related to prevalent cardiometabolic risk factors."
© 2020 HealthDay. All rights reserved.
Posted: April 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.